495 related articles for article (PubMed ID: 27825515)
1. Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model.
Tanaka N; Mizuno R; Yasumizu Y; Ito K; Shirotake S; Masunaga A; Ito Y; Miyazaki Y; Hagiwara M; Kanao K; Mikami S; Nakagawa K; Momma T; Masuda T; Asano T; Oyama M; Oya M
Urol Oncol; 2017 Feb; 35(2):39.e19-39.e28. PubMed ID: 27825515
[TBL] [Abstract][Full Text] [Related]
2. Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy.
Templeton AJ; Knox JJ; Lin X; Simantov R; Xie W; Lawrence N; Broom R; Fay AP; Rini B; Donskov F; Bjarnason GA; Smoragiewicz M; Kollmannsberger C; Kanesvaran R; Alimohamed N; Hermanns T; Wells JC; Amir E; Choueiri TK; Heng DY
Eur Urol; 2016 Aug; 70(2):358-64. PubMed ID: 26924770
[TBL] [Abstract][Full Text] [Related]
3. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.
Ko JJ; Xie W; Kroeger N; Lee JL; Rini BI; Knox JJ; Bjarnason GA; Srinivas S; Pal SK; Yuasa T; Smoragiewicz M; Donskov F; Kanesvaran R; Wood L; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Choueiri TK; Heng DY
Lancet Oncol; 2015 Mar; 16(3):293-300. PubMed ID: 25681967
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with metastatic renal cell carcinoma receiving targeted therapy.
Zhang GM; Zhu Y; Gu WJ; Zhang HL; Shi GH; Ye DW
Int J Clin Oncol; 2016 Apr; 21(2):373-378. PubMed ID: 26335242
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy.
Takagi T; Fukuda H; Kondo T; Ishihara H; Yoshida K; Kobayashi H; Iizuka J; Okumi M; Ishida H; Tanabe K
Target Oncol; 2019 Apr; 14(2):179-186. PubMed ID: 30927174
[TBL] [Abstract][Full Text] [Related]
6. Incorporating Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio in Place of Neutrophil Count and Platelet Count Improves Prognostic Accuracy of the International Metastatic Renal Cell Carcinoma Database Consortium Model.
Chrom P; Stec R; Bodnar L; Szczylik C
Cancer Res Treat; 2018 Jan; 50(1):103-110. PubMed ID: 28253564
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma.
Kuzman JA; Stenehjem DD; Merriman J; Agarwal AM; Patel SB; Hahn AW; Alex A; Albertson D; Gill DM; Agarwal N
BMC Urol; 2017 Jan; 17(1):1. PubMed ID: 28056941
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.
Davis ID; Xie W; Pezaro C; Donskov F; Wells JC; Agarwal N; Srinivas S; Yuasa T; Beuselinck B; Wood LA; Ernst DS; Kanesvaran R; Knox JJ; Pantuck A; Saleem S; Alva A; Rini BI; Lee JL; Choueiri TK; Heng DYC
Eur Urol; 2017 Jun; 71(6):970-978. PubMed ID: 27771126
[TBL] [Abstract][Full Text] [Related]
9. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
10. Effect of hypertension on preoperative neutrophil-lymphocyte ratio evaluation of prognosis of renal cell carcinoma.
Sun J; Ning H; Sun J; Qu X
Urol Oncol; 2016 May; 34(5):239.e9-15. PubMed ID: 26803433
[TBL] [Abstract][Full Text] [Related]
11. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
[TBL] [Abstract][Full Text] [Related]
12. Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings.
Tanaka N; Mizuno R; Shirotake S; Ito K; Yasumizu Y; Masunaga A; Ito Y; Miyazaki Y; Hagiwara M; Kanao K; Mikami S; Nakagawa K; Momma T; Masuda T; Asano T; Oyama M; Oya M
Urol Oncol; 2016 Jul; 34(7):293.e17-25. PubMed ID: 27040380
[TBL] [Abstract][Full Text] [Related]
13. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
de Velasco G; Culhane AC; Fay AP; Hakimi AA; Voss MH; Tannir NM; Tamboli P; Appleman LJ; Bellmunt J; Kimryn Rathmell W; Albiges L; Hsieh JJ; Heng DY; Signoretti S; Choueiri TK
Oncologist; 2017 Mar; 22(3):286-292. PubMed ID: 28220024
[TBL] [Abstract][Full Text] [Related]
14. The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma.
Aktepe OH; Güner G; Güven DC; Şahin TK; Ardıç FS; Yüce D; Yalçın Ş; Erman M
Turk J Med Sci; 2021 Apr; 51(2):757-765. PubMed ID: 33350295
[TBL] [Abstract][Full Text] [Related]
15. Development of novel ACN (albumin, C-reactive protein and neutrophil-to-lymphocyte ratio) prognostication model for patients with metastatic renal cell carcinoma receiving first-line molecular-targeted therapy.
Tamura K; Ando R; Takahara K; Ito T; Kanao K; Yasui T; Shiroki R; Miyake H
Urol Oncol; 2021 Jan; 39(1):78.e1-78.e8. PubMed ID: 32958444
[TBL] [Abstract][Full Text] [Related]
16. The Role of Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Platelets in the Prognosis of Metastatic Renal Cell Carcinoma.
Huszno J; Kolosza Z; Mrochem-Kwarciak J; Rutkowski T; Skladowski K
Oncology; 2019; 97(1):7-17. PubMed ID: 31048577
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of the efficacy of the pretreatment neutrophil-to-lymphocyte ratio as a predictor of prognosis in renal carcinoma patients receiving tyrosine kinase inhibitors.
Na N; Yao J; Cheng C; Huang Z; Hong L; Li H; Qiu J
Oncotarget; 2016 Jul; 7(28):44039-44046. PubMed ID: 27270655
[TBL] [Abstract][Full Text] [Related]
18. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab.
Simonaggio A; Elaidi R; Fournier L; Fabre E; Ferrari V; Borchiellini D; Thouvenin J; Barthelemy P; Thibault C; Tartour E; Oudard S; Vano YA
Cancer Immunol Immunother; 2020 Dec; 69(12):2513-2522. PubMed ID: 32561968
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
[TBL] [Abstract][Full Text] [Related]
20. Is the pretreatment neutrophil to lymphocyte ratio an important prognostic parameter in patients with metastatic renal cell carcinoma?
Cetin B; Berk V; Kaplan MA; Afsar B; Tufan G; Ozkan M; Isikdogan A; Benekli M; Coskun U; Buyukberber S
Clin Genitourin Cancer; 2013 Jun; 11(2):141-8. PubMed ID: 23083797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
